The GH secretagogue hexarelin reduced neonatal brain injury and activated Akt/GSK-3β neuroprotective signaling pathways, demonstrating direct neuroprotection independent of GH release for birth-related brain damage.
Key findingHexarelin reduced neonatal brain injury in a hypoxia-ischemia model and altered Akt/GSK-3β phosphorylation — activating pro-survival signaling cascade
What the researchers found
Hexarelin reduced neonatal brain injury in a hypoxia-ischemia model and altered Akt/GSK-3β phosphorylation — activating pro-survival signaling cascades for direct GH-independent neuroprotection in the developing brain.
Why it matters
Relevant for ghrp, neuroprotection, receptor-signaling.
How the study worked
animal-study study on ghrp, neuroprotection.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide research with translational implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation.
Endocrinology, 146(11), 4665-72
Citation
Brywe, Katarina G; Leverin, Anna-Lena; Gustavsson, Malin; Mallard, Carina; Granata, Riccarda; Destefanis, Silvia; Volante, Marco; Hagberg, Henrik; Ghigo, Ezio; Isgaard, Jörgen. (2005). Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3beta phosphorylation.. Endocrinology, 146(11), 4665-72.